Time to renal disease and end-stage renal disease in PROFILE: A multiethnic lupus cohort

PLoS Medicine

Volumn 3, Issue 10, 2006, Pages 1949-1956

  Alarcón, Graciela S ^a   McGwin Jr , Gerald ^b   Petri, Michelle ^c   Ramsey Goldman, Rosalind ^d   Fessler, Barri J ^a   Vilá, Luis M ^e   Edberg, Jeffrey C ^a   Reveille, John D ^f   Kimberly, Robert P ^a  

^a University of Alabama at Birmingham   (United States)

^b Kentucky   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VALINE; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; HLA ANTIGEN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; ETHNOLOGY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RACE DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PUERTO RICO; TIME;

ADULT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA ANTIGENS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PUERTO RICO; RECEPTORS, IGG; TEXAS; TIME FACTORS;

EID: 33750887728     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030396     Document Type: Article

References (39)

1. Ward MM, Studenski S (1992) Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med 152: 2082-2088.
2. Stewart M, Petri M (2000) Lupus nephritis outcomes: Health maintenance organizations compared to non-health maintenance organizations. J Rheumatol 27: 900-902.
3. Kimberly RP, Lockshin MD, Sherman RL, Beary JF, Mouradian T, et al. (1981) "End-stage" lupus nephritis: Clinical course to and outcome on dialysis. Experience with 39 patients. Medicine 60: 277-287.
4. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M (1991) Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status. Am J Med 91: 345-353.
5. Petri M (1998) The effect of race on incidence and clinical course in systemic lupus erythematosus: The Hopkins Lupus Cohort. J Am Med Womens Assoc 53: 9-12.
6. Cooper GS, Parks CG, Treadwell EL, St.Clair EW, Gilkeson GS, et al. (2002) Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 11: 161-167.
7. Ward MM, Studenski S (1990) Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. Arch Intern Med 150: 849-853.
8. Karlson EW, Daltroy LH, Lew RA, Wright EA, Partridge AJ, et al. (1997) The relationship of socioeconomic status, race and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 40: 47-56.
9. Alarcón GS, McGwin G Jr, Bartolucci AA, Roseman J, Lisse J, et al. (2001) Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 44: 2797-2806.
10. Alarcón GS, Roseman JM, McGwin G Jr, Uribe A, Bastian HM, et al. (2004) Systemic lupus erythematosus in three ethnic groups: XX. Damage as predictor of further damage. Rheumatology 43: 202-205.
11. Sutcliffe N, Clarke AE, Gordon V, Farewell V, Isenberg DA (1999) The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology 38: 1130-1137.
12. Johnson AE, Gordon C, Palmer RG, Bacon PA (1995) The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 38: 551-558.
13. Nath SK, Kilpatrick J, Harley JB (2004) Genetics of human systemic lupus erythematosus: The emerging picture. Curr Opin Immunol 16: 794-800.
14. Croker JA, Kimberly RP (2005) Genetics of susceptibility and severity in systemic lupus erythematosus. Curr Opin Rheumatol 17: 529-537.
15. Croker JA, Kimberly RP (2005) SLE: Challenges and candidates in human disease. Trends Immunol 26: 580-586.
16. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, et al. (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38: 550-555.
17. Karassa FB, Trikalinos TA, Ioannidis JPFcγRIIIA-SLE Meta-Analysis Investigators (2003) The FcγRIIIA-F158 allele is a risk factor for the development of lupus nephritis: A meta-analysis. Kidney Int 63: 1475-1482.
18. Seligman VA, Suarez C, Lum R, Inda SE, Lin D, et al. (2001) The Fcγ receptor IIIA-158F allele is a major risk factor for the development of lupus nephritis among Caucasians but not non-Caucasians. Arthritis Rheum 44: 618-625.
19. Karassa FB, Trikalinos TA, Ioannidis JPA (2002) Role of the Fcγ receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis. Arthritis Rheum 46: 1563-1571.
20. Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, et al. (2006) Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439: 851-855.
21. Alarcón GS, McGwin G Jr, Petri M, Reveille JD, Ramsey-Goldman R, et al. (2002) Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 11: 95-101.
22. Alarcón GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, et al. (1999) Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus 8: 197-209.
23. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277.
24. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
25. Gladman D, Urowitz M, Fortin P, Isenberg D, Goldsmith C, et al. (1996) Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. J Rheumatol 23: 1953-1955.
26. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, et al. (2000) The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 27: 373-376.
27. Edberg JC, Langefeld CD, Wu JM, Moser KL, Kaufman KM, et al. (2002) Genetic linkage and association of Fc gamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum 46: 2132-2140.
28. Bastian HM, Roseman JM, McGwin G Jr, Alarcón GS, Friedman AW, et al. (2002) Systemic lupus erythematosus in three ethnic groups: XII. Risk factors for lupus nephritis after diagnosis. Lupus 11: 152-160.
29. Marchini M, Antonioli R, Lleo A, Barili M, Caronni M, et al. (2003) HLA class II antigens associated with lupus nephritis in Italian SLE patients. Hum Immunol 64: 462-468.
30. Bagavant H, Deshmukh US, Gaskin F, Fu SM (2004) Lupus glomerulonephritis revisited 2004: Autoimmunity and end-organ damage. Scand J Immunol 60: 52-63.
31. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, et al. (1994) Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: International validation. J Rheumatol 21: 1468-1471.
32. Gladman DD, Ibañez D, Urowitz MB (2003) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29: 288-291.
33. Liang MH, Socher SA, Larson MG, Schur PH (1989) Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32: 1107-1118.
34. Liang MH, Fortin PR, Isenberg DA, Snaith L (1991) Quantitative clinical assessment of disease activity in systemic lupus erythematosus: Progress report and research agenda. Rheumatol Int 11: 133-136.
35. Freedman BI, Wilson CH, Spray BJ, Tuttle AB, Olorenshaw IM, et al. (1997) Familial clustering of end-stage renal disease in blacks with lupus nephritis. Am J Kidney Dis 29: 729-732.
36. Arce-Salinas CA, Vila AR, Martinez-Rueda JO, Munoz L, Cardiel MH, et al. (1995) Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: A case-control study. Lupus 4: 197-203.
37. Bruce IN, Gladman DD, Urowitz MB (2000) Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. Arthritis Care Res 13: 406-408.
38. Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE (1995) High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10: 1620-1628.
39. Dooley MA, Hogan S, Jennette C, Falk R (1997) Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 51: 1188-1195.